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Redefining postoperative surveillance after
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Britt H. Tonnessen, MD,a for the Zenith Investigators, New Orleans, La; Cleveland, Ohio; and
San Francisco, Calif
Introduction: Recommended postoperative surveillance after endovascular aneurysm repair (EVAR) includes serial
contrast-enhanced CT scans. The cumulative deleterious effect on renal function, radiation exposure, and significant cost
of this surveillance regimen are all problematic. However, there are scant data to support modulation of current
post-EVAR surveillance regimens.
Methods:The study comprised patients who underwent EVAR as part of the prospective multicenter pivotal (phase II) and
continued-access (phase III) US Zenith Endovascular (Cook, Bloomington, Ind) graft trials. A core lab prospectively
recorded patient data. A composite aneurysm-related morbidity (ARM) variable was calculated to include aneurysm
rupture, open conversion, any secondary intervention, limb thrombosis, migration, renal morbidity, or aneurysm-related
death. The long-term freedom from ARM as a function of the presence or cumulative absence of any endoleak at 1, 6, and
12 months was analyzed. The potential additive predictive utility of aneurysm sac shrinkage (>5 mm) was assessed at 12
months. The instructions for use for aortic neck anatomy (>15 mm length, 18 to 28 mm diameter, <60° angulation)
were followed.
Results: EVARwas done in 739 patients (mean follow-up, 29.9 17.1 months). Freedom from endoleak at 1 month was
highly predictive (P < .001) of reduced ARM: freedom from ARM was 92.3%, 89.8%, 85.2%, 83.1% and 83.1 % at 1, 2,
3, 4, and 5 years, respectively, in patients without endoleak (83.1%) and 75%, 67.1%, 61.5%, 55.9%, and 55.9% in patients
with endoleak (16.9%). Cumulative absence of endoleak at 1 year (77.6%) was associated with 94%, 91.5%, 88.1%, 85.8%,
and 85.8% 1- to 5-year freedom from ARM vs 73.3%, 66.7%, 56.6%, 52.5%, and 52.5% in patients with endoleak<1 year
(22.4%), P < .001. In patients without endoleak at 12 months, the subsequent risk of any ARM was 8.2% (5-year risk,
14.2%; 1-year risk, 6.0%). In patients with significant sac shrinkage (>5 mm) and cumulative absence of endoleak at 12
months, the subsequent risk of an ARM was 5.3% (5-year risk, 11.1%; 1-year risk, 5.8%).
Conclusions:Absence of endoleak at 30 and 365 days predicted greatly improved long-term freedom fromARM compared
with early endoleak. A new EVAR surveillance regimen is recommended that modulates the intensity and frequency of
postoperative imaging based on these early outcomes. In patients without early endoleak, the 6-month surveillance is
eliminated, and aortic ultrasound is suggested for long-term surveillance >1 year. In most patients, this reduced
surveillance regimen would be appropriate and could improve patient safety by reducing the cumulative deleterious
effects of intravenous contrast and radiation exposure while also reducing health care costs. These subjective recommen-
dations would be ideally validated in a randomized, prospective trial. ( J Vasc Surg 2008;48:278-85.)The predictive power of early outcome metrics on
long-term results after endovascular aneurysm repair
(EVAR) of abdominal aortic aneurysm (AAA) is unclear.
The results of prior studies from single-device multicenter
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278trials and large European multiple-device experiences have
been conflicting.1,2 The reasons are likely multifactorial,
including differing methods and intensity of surveillance,
use of core laboratory vs investigator reported data, varia-
tions in length of follow-up, and finally, the use of various
endografts. Does the presence of an early endoleak after
EVAR have significant prognostic value in long-term out-
come? This clinical question is a potentially important one,
because it could have implications regarding the level of
aggressiveness required for long-term surveillance for these
patients.
Surveillance regimens for EVAR that are the current
standard-of-care were derived empirically from early multi-
center trials and codified in the instructions for use (IFU)
for the devices. Because long-term data were not available
at that time, these surveillance regimens were not data-
driven. Current recommended EVAR surveillance regi-
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scans and four-view plain abdominal radiographs (KUBs) at
1, 6, and 12 months and yearly thereafter. The cumulative
contrast load from these CT scans is worrisome for its
deleterious effect on renal function.3,4 The potential carci-
nogenic effects of the cumulative radiation dose for patients
is more difficult to quantify but still troubling.5,6 Finally,
the cost associated with current EVAR surveillance regi-
mens is significant, comprising 30% to 35% of the total costs
of EVAR follow-up during a 5-year period.7
The purpose of this study was to examine the correla-
tion of early endoleaks with the long-term outcome in
patients treated in the Zenith (Cook Inc, Bloomington,
Ind)United States (US)multicenter trial, assessing possible
correlation with early endoleak. On the basis of these data,
alteration of current surveillance regimens may be appro-
priate.
METHODS
This study is 5-year retrospective analysis of prospec-
tively collected multicenter data from the US Zenith endo-
vascular AAA pivotal (phase II) and continued-access
(phase III) trials. The patients were enrolled between Jan-
uary 26, 2000, and June 18, 2003, and the follow-up was
current to January 10, 2007. All data presented were pro-
spectively collected by a core lab facility, the details of
which have been previously described,8,9 as has been a
comprehensive list of inclusion/exclusion criteria.9 Aortic
neck requirements included a minimum aortic neck length
of 15mm, a diameter of 28 mm and 18 mm, with a
10% change in diameter in the first 15 mm of the neck.
Angulation of the aortic neck to the aneurysm sac or the
suprarenal aorta was limited to 60° and 45°, respec-
tively.
The surveillance regimen included four-viewKUBs and
intravenous (IV) contrast- and noncontrast-enhanced CT
scanning at 1, 6, and 12 months, and yearly thereafter. The
study protocol mandated a CT slice thickness of 3 mm.
All CT scan measurements and endoleak assessments were
performed by the blinded core lab facility. Endoleak assess-
ment was possible only if both noncontrast and contrast
films were available.
Definitions. An aneurysm-related morbidity (ARM)
variable was calculated to use as a composite end point to
characterize patients who had any adverse outcome after
EVAR. The ARM included aneurysm-related death, AAA
rupture, open conversion, any secondary intervention, limb
thrombosis, migration, renal morbidity, bowel fistula, or
pseudoaneurysm. Significant migration was defined ac-
cording to the Society for Vascular Surgery reporting stan-
dards10 as 10 mm caudal movement or any movement
requiring treatment. Renal morbidity was defined as renal
failure requiring dialysis. Early endoleak was defined as one
seen at the 30-day CT scan.
Statistics. Data were managed by MED Institute
(West Lafayette, Ind) using an Interactive Data Entry Sys-
tem (IDES) database (Corel Paradox tables, Corel Corp,
Ottawa, Ontario, Canada). Data were analyzed using SAS 8software (SAS Institute Inc, Cary, NC). Kaplan-Meier life-
table analysis was used to estimate ARM rates at 1, 2, 3, 4,
and 5 years of follow-up in patients with and without any
endoleak. The log-rank test was used to test for a difference
in the freedom frommorbidity functions among the patient
cohorts.
RESULTS
A total of 739 patients underwent EVAR in the US
Zenith endovascular trials, 352 in the pivotal (phase II) trial
and 387 in continued-access (phase III) trial. The mean
follow-up for the entire cohort was 29.9 17.1 months. A
small number of patients who did not have the requisite
imaging were censored from the study, and a total of 714
patients were analyzed in this report.
Table I provides the 1-, 3-, and 5-year calculated risk of
adverse outcomes in the entire patient cohort, those with
endoleak at 30 days, and those with cumulative absence of
endoleak at 30 days and 1 year. The presence of endoleak at
30 days (16.9%, 121 of 714) was associated with a signifi-
Table I. Rate of morbidities from Kaplan-Meier analysis
Morbidity
1 year, %
(No.)a
3 year, %
(No.)
5 year, %
(No.)
Aneurysm-related death
Entire cohort 1.9 (736) 2.8 (497) 2.8 (155)
Endoleak at 30 days 1.7 (121) 5.5 (83) 5.5 (21)b
No endoleak at 30 days 0.9 (593) 1.2 (406) 1.2 (133)
No endoleak at 1 year 0.9 (554) 1.3 (381) 1.3 (126)
Open conversion
Entire cohort 0.7 (736) 1.0 (497) 1.7 (155)
Endoleak at 30 days 0.9 (121) 0.9 (83) 5.6 (21)c
No endoleak at 30 days 0.2 (593) 0.6 (406) 0.6 (133)
No endoleak at 1 year 0.2 (554) 0.6 (381) 0.6 (126)
Migration
Entire Cohort 0 (625) 0.4 (478) 0.4 (152)
Endoleak at 30 days 0 (109) 0 (83) 0 (21)
No endoleak at 30 days 0 (513) 0.5 (393) 0.5 (130)
No endoleak at 1 year 0 (482) 0.6 (368) 0.6 (123)
Rupture
Entire cohort 0.1 (736) 0.1 (497) 0.1 (155)
Endoleak at 30 days 0 (121) 0 (83) 0 (21)
No endoleak at 30 days 0.2 (593) 0.2 (406) 0.2 (133)
No endoleak at 1 year 0.2 (554) 0.2 (381) 0.2 (126)
Secondary interventions
Entire cohort 9.4 (734) 16.4 (439) 19.0 (124)
Endoleak at 30 days 23.7 (121) 36.7 (57) 42.4 (10)d
No endoleak at 30 days 6.5 (591) 12.4 (376) 14.6 (114)
No endoleak at 1 year 4.7 (552) 9.3 (357) 11.7 (111)e
Limb thrombosis
Entire cohort 1.9 (734) 2.6 (486) 2.6 (152)
Endoleak at 30 days 0 (121) 0 (83) 0 (21)
No endoleak at 30 days 2.4 (591) 3.1 (395) 3.1 (130)
No endoleak at 1 year 2.5 (552) 3.4 (370) 3.4 (123)
Renal morbidity
Entire cohort 1.1 (736) 1.5 (494) 1.5 (155)
Endoleak at 30 days 0.9 (121) 0.9 (83) 0.9 (21)
No endoleak at 30 days 0.8 (593) 1.3 (404) 1.3 (133)
No endoleak at 1 year 0.9 (554) 1.4 (379) 1.4 (126)
aData in parenthesis are patients at risk; bP  .08; cP  .16; dP  .001;
eP  .001 vs cohort without endoleak at 30 days.cantly increased need for secondary procedures at 5 years
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P  .001). Nonsignificant differences were noted in the
5-year risk of aneurysm-related death (5.5% vs 1.2%, P 
.08) and open conversion (5.6% vs 0.6%, P  .16) in
patients with and without an endoleak at 30 days, respec-
tively.
Patients with absence of early (30-day) endoleak
(83.1%, 593 of 714), had a significant reduction (P .001)
in ARM events at 1, 2, 3, 4, and 5 years compared with
those patients with any endoleak at 30 days (16.9%, 121 of
714; Fig 1). These differences were seen by 1 year, as those
patients without early endoleak had a 1-year freedom from
ARMof 92.3 % compared with 75.0% in those patients with
early endoleak. These significant differences in occurrence
rates of ARMbetween the two cohorts weremagnified with
long-term follow-up. At 5 years, the freedom from ARM in
those with an early endoleak fell to 55.9%, significantly less
than the 83.1% freedom from ARM in patients without
early endoleak.
Patients with cumulative absence of endoleak at 6
months (79.4%, 567 of 714) and 12months (77.6%, 554 of
714) had an identical 5-year freedom from ARM of 85.8%,
a difference of only 2.7% improvement from the 30-day
group (Fig 2). Thus, surveillance for continued absence of
endoleak at 6 and 12 months did not greatly alter the
predicted 5-year freedom from ARM. In the 343 patients
(59.7%) with cumulative absence of endoleak at 1 year and
significant (5 mm) aneurysm sac shrinkage, the 5-year
Fig 1. Kaplan-Meier plots of freedom from aneurysm-related
morbidity in patients with (solid line) or without endoleak (dashed
line) during the first 30 days.freedom from ARM rose to 88.9% (Fig 3).Fig 4 demonstrates the freedom from ARM in those
without (74.4%, 531 of 714), or with endoleak (25.6%,
183 of 714) at any time interval during the study. The
5-year freedom from ARM in patients without endoleak at
any time in the study was 89.5% vs 49.8% in those with
endoleak (P .001). In patients without endoleak, 75% of
ARM events (52 of 69) occurred within the first 12 months
(Table II).
In patients with no endoleak at 12 months, the subse-
quent risk of any ARM was 8.2% (5-year risk, 14.2%; 1-year
risk, 6.0%; Fig 2). In patients with significant sac shrinkage
(5 mm) and cumulative absence of endoleak at 12
months, the subsequent risk of an ARM was just 5.3%
(5-year risk, 11.1%; 1-year risk, 5.8%; Fig 3).
DISCUSSION
There are several important observations from these
data:
1. The absence of early endoleak identifies a patient cohort
at substantially reduced risk for subsequent ARM. These
Fig 2. Kaplan-Meier plots of freedom from aneurysm-related
morbidity in patients with no endoleaks up to 30 (dotted line), 180
(dotted-dashed line), and 365 (dashed line) days.patients may be candidates for a more relaxed regimen of
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endoleak at 12months and significant aneurysm shrinkage
had a subsequent risk for ARM of just 5.3%.
2. The presence of any endoleak at 30 days defines a
patient at high risk for subsequent ARM (44.1% at 5
years). These patients should have aggressive surveil-
lance and treatment as indicated.
3. The absence of endoleak does not confer immunity for
all ARM. There was a 10.5% risk of ARM at 5 years in
patients who never experienced an endoleak. The etiol-
ogy of ARM is multifactorial and is likely not totally
preventable or predictable with any imaging regimen.
Absence of early endoleak. At 30 days, 593 of the
714 patients (83.1%) treated with Zenith endografts had
no endoleak, and this cumulative absence of endoleak
continued to 1 year in 554 (77.6%). Thus, most patients
treated with the Zenith endograft would be candidates for
a reduced surveillance regimen. The 6-month surveillance
studies in these patients did not correlate with any differ-
ence in 5-year ARM compared with the 12-month data, so it
seems reasonable to delete this imaging completely if there is
no early (30-day) endoleak. These findings are consistent with
those of a recently presented single-center experience.11
Those patientswith a cumulative absence of endoleak at 1 year
had a projected 5-year risk of ARM of 14.2%.
Because there was a 6.0% risk of ARM in the first 12
months in this cohort, the subsequent predicted risk of
ARM to 5 years was 8.2%. In those patients with cumulative
Fig 3. Kaplan-Meier plots of freedom from aneurysm-related
morbidity patients with (solid line) endoleaks and no sac shrinkage
or those without endoleak (dashed line) and with sac shrinkage in
the first year.absence of endoleak at 12 months and significant AAAshrinkage, the subsequent risk of ARM at 5 years was 5.3%.
In these groups, the low risk of subsequent events sug-
gested that a reduced surveillance regimen is reasonable.
The finding that 10.5% of patients are projected to experi-
ence some form of ARM at 5 years despite the cumulative
absence of endoleak is perhaps surprising. It is possible that
an endoleak could have been missed, but the objective,
blinded interpretation of the images by a core lab facility, as
in this study, would minimize this occurrence.
Although the primary emphasis of surveillance has been
to identify endoleak and potential aneurysm sac enlarge-
ment, it is clear from these data that the absence of these
markers does not confer complete protection from ARM.
Some ARM is not predictable by or correlated with en-
doleak, including limb thrombosis requiring a secondary
procedure, renal morbidity, and endograft infection requir-
ing open conversion. These were all exceptionally uncom-
mon events in this study (Table II), but together they
contributed to a large percentage of ARM. Although sur-
veillance for endoleak is important and has been the pri-
mary focus of follow-up, it does not appear to be the sine
qua non. The etiology of ARM is multifactorial and is likely
not totally preventable or predictable with any imaging
regimen.
Presence of early endoleak. Endoleak at 30 days was
uncommon in this large patient cohort, occurring in 16.9%
(121 of 714) of the treated subjects. An endoleak at this
early time interval correlated with a 44.1% risk of ARMover
5 years. Most of these endoleaks were type II.9 These data
Fig 4. Kaplan-Meier plots of freedom from aneurysm-related
morbidity in patient groups with absence (solid line) or presence
(dashed line) of endoleak through the study.confirm prior reports that early type II leaks are not neces-
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from the European Collaborators on Stent/Graft Tech-
niques for Aortic Aneurysm Repair (EUROSTAR) data-
base (n 3595).12 In a study where a variety of endografts
were used, patients with type II endoleaks were found to
have an increased composite adverse event rate (AAA
growth, transfemoral or transabdominal reintervention) of
55% vs 15% after 3 years.12 The long-term results from the
current study underscore that these patients should have
intensified surveillance.
New surveillance regimen. On the basis of these data
and 5-year outcomes, we propose a modified surveillance
regimen for patients undergoing EVAR with the Zenith
endograft (Fig 5). All patients should have a contrasted CT
scan and four-view KUBs at 30 days postprocedure. If there
is any endoleak, or less than one stent component or iliac
overlap, an intensified surveillance should be undertaken,
consisting of serial IV contrast-enhanced CT scans at a
minimum time interval of every 6 to 12 months. Four-view
KUBs should also be considered. Subsequent treatment
Table II. Aneurysm-related morbidity by time for patient
Type of morbidity 0-30 days, % (No.)a 31-180
Patients at risk 531
Patients with 1 event 2.82 (15) 2.
Related death 0.19 (1) 0.
Rupture 0.0 (0) 0
Conversion 0.0 (0) 0
Secondary intervention
Other 1.13 (6) 0.
Leak 0.0 (0) 0.
Occlusion 1.51 (8) 0.
Limb thrombosis 1.69 (9) 0.
Renal 0.19 (1) 0.
Pseudoaneurysm 0.0 (0) 0
Bowel fistula 0.0 (0) 0
aData in parenthesis are the number of events.
Fig 5. New surveillance protocol for Zenith endografts. CT,
computed tomography; IV, intravenous; KUB, plain abdominal
radiographs; U/S, ultrasound.should be performed as indicated.In patients with no early (30-day) endoleak and satis-
factory component/iliac overlap, a reduced surveillance
regimen is appropriate. No 6-month imaging is recom-
mended. At the 12-month follow-up, a contrast-enhanced
CT scan is recommended. If there is no endoleak and a
stable or shrinking aneurysm sac, a yearly aortic ultrasound
examination is then suggested. If the patient’s body habitus
or other technical issues preclude an adequate examination
by ultrasound, then a noncontrast CT scan should be
substituted. An increasing aneurysm sac or new endoleak
should prompt more intensive imaging and treatment as
appropriate.
This suggested new surveillance regimen is predicated
on the low risk of ARM in patients without early endoleak
and the ability of aortic ultrasound imaging to detect
evidence of significant aneurysm sac repressurization, as
manifest by an increasing sac size or endoleak, or both. The
low risk of ARM is strongly supported by the results from
this large patient cohort, the prospective multicenter data
collection, and blinded interpretation of the imaging.
However, the recommendation of this new surveillance
regimenmust be considered subjective, because no data are
available demonstrating long-term outcomes in patients
followed up with such an altered surveillance regimen.
Other investigators have also recently suggested changes in
surveillance after EVAR, which include noncontrast CT
scans or ultrasound imaging for long-term surveil-
lance.13,14 Ideally, these recommendations should be vali-
dated with a prospective randomized trial comparing the
different surveillance regimens.
Eliminating the 6-month surveillance entirely and
changing the yearly surveillance to an aortic ultrasound
scan in those qualifying patients as above could have several
salutary effects. Most patients would not require the cumu-
lative IV contrast load and radiation exposure inherent in
serial CT scanning. Prior studies have demonstrated a
decline in renal function in EVAR patients. Interestingly,
there have been no differences in devices with or without
suprarenal fixation.15 The cumulative contrast load from
hout endoleak throughout the study
% (No.) 181-365 days, % (No.) 365 days, % (No.)
531 531
3) 1.13 (6) 2.64 (14)
) 0.0 (0) 0.38 (2)
) 0.19 (1) 0.0 (0)
) 0.19 (1) 0.38 (2)
) 0.56 (3) 0.56 (3)
) 0.0 (0) 0.56 (3)
) 0.38 (2) 0.19 (1)
) 0.38 (2) 0.75 (4)
) 0.0 (0) 0.38 (2)
) 0.0 (0) 0.0 (0)
) 0.0 (0) 0.0 (0)s wit
days,
531
45 (1
75 (4
.0 (0
.0 (0
56 (3
19 (1
56 (3
56 (3
75 (4
.0 (0
.0 (0the CT scans has been implicated for the deterioration in
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cumulative radiation exposure from CT scanning is trou-
blesome and becoming better understood.5,6
Finally, this new surveillance paradigm has the potential
for significant cost savings. Costs of imaging constitute 30% to
35% of the total postimplant costs during the 5-year period
after EVAR.7 Aortic ultrasound imaging is less expensive and,
most importantly, has zero potential morbidity.
The four-view KUBs were a part of the original surveil-
lance regimen to identify failure in the metallic support
system (stent fracture, barb separation, suprarenal stent
detachment) and assess adequacy of component overlap.
Stent fracture and barb separation were very uncommon in
this trial16 and, most importantly, had no discernible clin-
ical impact. Barb separation could theoretically weaken the
active proximal fixation and thus increase the risk of migra-
tion. However, only two episodes of migration were ob-
served in this large patient cohort, giving a 5-year freedom
frommigration of 99.6%.16 Two episodes of detachment of
the suprarenal stent from themain body were noted early in
the Zenith experience, but this has not occurred since the
suture connections were reinforced in 2002.
Confirmation of adequate component and iliac overlap
is important initially. As such, a set of four-view KUBs was
retained in the initial 30-day imaging. Indeed, the single
AAA rupture after EVAR in this entire cohort occurred in a
patient with inadequate overlap of a limb into the iliac
artery.9 The risk of subsequent late component separation
has been very rare, occurring in only three patients.16
Although an initial four-view KUB is still considered pru-
dent, the rarity of clinically significant problems on serial
studies suggests that this imaging could be omitted for
most patients. In patients with any combination of a very
large AAA or significant iliac or aortic tortuosity, greater
stress on the components may occur as the sac shrinks, and
continued use of KUB surveillance may be prudent.
The risk of subsequent ARM in the reduced surveil-
lance group is low, but it would be inappropriate to per-
form no long-term surveillance at all. Although some of
these ARM events are not related to endoleak, some clearly
are and should be readily identified by an enlarging aneu-
rysm sac or endoleak, or both, seen on ultrasound. In the
Zenith study, there was a 12% to 15 % risk of late endoleak
occurring when none was detected at 30 days.16 Most of
these endoleaks were type II in nature. The ultimate clinical
impact of these late endoleaks is uncertain, but it is prudent
to continue some sort of longitudinal imaging in all pa-
tients undergoing EVAR.
Limitations. The EVAR surveillance recommenda-
tions are based on data from a single device. As such, they
must be considered device-specific and not be used with
other devices. Serial CT scanning is the only reliable
method of detecting endograft migration and should con-
tinue to be an integral part of surveillance regimens for
devices with a significant risk of this failure mode.17-19
These long-termdata are frompatients who had stringent
aortic neck inclusion criteria. Patients treated with Zenith
endografts who are outside the device IFU, particularly thosewith disadvantaged aortic necks, may not have the same
long-term results. As such, use of these new surveillance
regimens cannot be recommended in these patients.
Five-year follow-up was not available for the entire
cohort because the original study design only included 2
years of follow-up. Exhaustive efforts were made to obtain
consent from patients in the pivotal arm to extend their
follow-up to 5 years. The continued-access patients did not
have follow-up after 2 years in the trial. To minimize any
bias in the long-term results, Kaplan-Meier analysis was
used to properly estimate occurrence rates, taking into
account the censored patients.
CONCLUSIONS
The large majority of patients undergoing EVAR with
the Zenith endograft have absence of endoleak at 30 and
365 days. In these patients, a reduced surveillance regimen
is recommended that may improve patient safety by reduc-
ing the cumulative deleterious effects of IV contrast and
radiation exposure while also reducing health care costs.
The small number of patients who have early endoleak are
at higher risk for subsequent events and need more aggres-
sive surveillance and treatment as indicated. Finally, although
surveillance for endoleak has been a primary focus of follow-
up, it does not appear to be the sine qua non. The etiologies of
ARM are multifactorial and are likely not totally preventable
or predictable with any imaging regimen.
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Dr Blair A. Keagy (Chapel Hill, NC). We have been privi-
leged to hear a presentation by some of the leaders in the field of
endovascular aneurysm repair. Their experience is noteworthy and
the quality of their work speaks for itself. I have several comments
regarding the statistics used in this manuscript. The authors have
convincingly shown that the presence or absence of an endoleak at
30 days is predictive of a subsequent adverse event. I performed a
2 analysis on their data correlating the 30-day leak with a 1-year
adverse event rate and this again supports the validity of their
thesis.
However, if this parameter is to be used as a screening test, the
predictive value is important, which is defined as the probability
that the test is correct when applied to the individual patient in
the population of interest. When making such calculation, based
theorem assumes importance. Based theorem says that the predic-
tive value of a diagnostic study is dependent on the prevalence in
the disease in the population of interest. With my calculations, I
made the assumption of a 15% endoleak rate, which was based on
the essay author’s observations. The formula predictive value is
true positives divided by true positives plus false positives. This
would result in a predictive value for this screening test of 37%.
This may not be acceptable for making decisions regarding further
follow-up.
I would also question the definition of adverse events. These
are listed as rupture open conversion, any secondary intervention
linked thrombosis migration, renal morbidity, valve expansion due
to pseudoaneurysm. In the abstract, it is stated that the adverse
event rate was retrospectively calculated. This could be construed
as a form of data mining and would mandate a further prospective
study.
The investigators used a Kaplan-Meier or life-table analysis in
their study. In the 5 years, the number of actual patients was less
than 20% of the original cohort. Therefore, it would have been
helpful if standard error bars had been included on the graphs.
The investigators mentioned the use of ultrasound in their
paper as a means of long-term follow-up, but gave no details of
when it was employed in this report. Also, they do not comment on
whether or not they used an implanted pressure sensor in any ofI agree with the authors’ concern as to the risk of repeated CT
scans, including renal failure cost and a potential cardiogenic risk.
It is stated that many of the endoleaks in this study were type II and
that many of these types of endoleaks may not be benign. I would
appreciate more information on how type II endoleaks should be
treated. In summary, I commend the authors on their presentation
and the quality of their work. To summarize my questions, they
are:
1. Are the authors satisfied with the presence of a 30-day or 1-year
endoleak rate as a sufficient screening test to change the way in
which vascular aneurysm patients are followed?
2. What other modalities such as ultrasound or pressure sensor
implantation would be helpful in following patients after endo-
vascular aneurysm repair?
3. How should type II endoleaks be followed?
4. Is the retrospective definition of adverse events acceptable?
5. How are patients with multiple adverse events handled in this
analysis?
DrW. Charles Sternbergh III. I appreciate those comments
and I will try to answer all those questions. Please prompt me if I
have missed any. Is it reasonable to change our surveillance algo-
rithm based on these data? That is really the crux of the question.
Those patients with no endoleak and a shrinking aneurysm sac at 1
year had a subsequent 5-year risk of aneurysm-related morbidity of
approximately 5%. While I don’t qualify as a statistician, it appears
to me that this adverse event rate is acceptably low. Those data
were really our basis for suggesting that we can change our
surveillance strategy.
One of the most important take home points is that those
patients with no endoleak throughout the entire study still had
about a 10% risk of some aneurysm-related morbidity. We have
always been keyed on looking at endoleak and the problems with
endoleak, but clearly that does not define all of the problems that
we see.
Regarding the second question concerning use of ultrasound
or pressure sensors, it was up to the investigator in terms of patients
with advanced renal insufficiency, whether or not they used ultra-
sound. It certainly wasn’t used routinely through the study, nor
were pressure sensors used.
JOURNAL OF VASCULAR SURGERY
Volume 48, Number 2 Rockman 285In terms of treatment of type II endoleak, that was up to the
investigator. Most of us tended to treat endoleaks only if the
aneurysms were increasing in size. Early in the experience, I
believe that majority of type II endoleaks treated were done by
in whom more relaxed surveillance regimens may be appropriate.
However, there was a 10.5% risk of ARM at 5 years in patients whocoil embolization. Translumbar glue embolization really wasn’t
being used with great frequency during this time, but perhaps
in the latter part of the trial, was used with some increased
frequency.INVITED COMMENTARYCaron Rockman, MD, New York, NY
The issue of the absolute necessity of life-long surveillance in
patients who have undergone endovascular abdominal aortic an-
eurysm repair (EVAR) is certainly an important and timely topic
from a number of perspectives. Clearly, there are appropriate
medical concerns regarding the repetitive use of iodinated contrast
materials and their possible cumulative deleterious effects on renal
function as well as apprehension regarding potential carcinogenic
consequences of recurring radiation exposure. In addition, the
issue of the societal cost of these studies cannot be completely
overlooked from a global health care standpoint.
To address these concerns, a variety of alternative forms of
surveillance in EVAR patients have been proposed, including
noncontrast computed tomography (CT) studies, traditional and
contrast-enhanced duplex ultrasound, gadolinium-enhanced mag-
netic resonance imaging, implantable wireless sac pressure sensors,
and intravascular ultrasound. However, currently the precise role
and accuracy of these alternatives remains ill defined.
The current study presents notable information. Patients with
an absence of early endoleak on a 30-day CT scan had a significant
reduction in aneurysm-related morbidity (ARM) at 1 to 5 years. It
should be noted, however, that although the definition of ARM
included obvious events such as aneurysm-related death, rupture,
endograft migration, and open conversion, it also included “sec-
ondary interventions,” which intuitively would be expected to be
more prevalent in patients with known endoleaks. Patients with a
cumulative absence of endoleak at 6 months (79.4% of patients)
and at 1 year (77.6% of patients), however, had an identical 5-year
freedom from any type of ARM. The authors state, therefore, that
routine surveillance for continued absence of endoleak at 6months
and 1 year did not greatly alter the predicted 5-year freedom from
ARM.
They conclude that the absence of an early endoleak therefore
identifies a cohort of patients at substantially reduced risk for ARMhad never experienced an endoleak. In addition, it is correctly
pointed out that not all ARM (for example, graft limb thrombosis)
will necessarily be predicted by an abnormality seen on a routinely
performed imaging study; nor can all ARM be prevented by even
very aggressive surveillance and monitoring programs.
Finally, in the Zenith trials there was a population of patients
in whom a delayed endoleak occurred: A 12% to 15% risk of late
endoleak, most often of type II, was noted even when no leak was
identified on the initial 30-day CT scan. The clinical significance of
these delayed leaks remains unclear. At our institution we have
anecdotally seen a number of patients in whom 3 or 4 years of
initially negative CT follow-up was subsequently followed by the
novel appearance of an endoleak on the next annual CT scan.
Several of these late leaks eventually required secondary interven-
tion and treatment.
The recommendations of the current study, although attrac-
tive, should be interpreted with caution. As the authors correctly
point out, these excellent results were obtained only using one type
of commercially available aortic stent graft system. In addition, and
perhaps even more importantly, these results were obtained in
patients who underwent intervention as part of a strictly controlled
clinical trial. As such, these patients represent a cohort of cases with
ideal anatomic parameters, and the long-term results are likely not
applicable to post-trial EVAR cases, in which preoperative ana-
tomic selection criteria is likely to have been relaxed by the indi-
vidual practitioner.
If the algorithm adopted in the article had been strictly fol-
lowed in this cohort of patients, this would have resulted in 23.4%
of patients having no routinely prescribed follow-up except for a
yearly ultrasound study after their negative result on the 1-year CT
scan. Even this excellent and compelling data and analysis do not
support such a radical change in follow-up protocols at the present
time. Although there undoubtedly exists a cohort of patients who
may not require lifelong intensive surveillance imaging after
EVAR, they remain imprecisely characterized at the present time.
